Frontiers in CAR-T Cell Therapy: Current Applications and Future Directions

Yizhou Huang

doi:10.54691/66356c27

Authors

Yizhou Huang

DOI:

https://doi.org/10.54691/66356c27

Keywords:

CAR-T cell therapy, immunotherapy, chimeric antigen receptor, hematologic malignancies, solid tumors, autoimmune diseases, cytokine release syndrome, neurotoxicity, antigen escape, tumor microenvironment.

Abstract

CAR-T cell therapy, an ascending star in the immunotherapy landscape, harnesses the patient's innate immune defenses to confront cancer and a spectrum of hematologic disorders, while also exhibiting promising avenues for application in other maladies. This comprehensive review delves into the fundamental mechanisms of CAR-T cell therapy, the evolution and design strategies of successive generations of CAR-T cells, as well as the advancements and clinical implementations achieved in treating a diverse array of diseases.

Downloads

Download data is not yet available.

References

[1] Jayaraman, J., et al., CAR-T design: Elements and their synergistic function. EBioMedicine, 2020. 58: p. 102931.

[2] Mohanty, R., et al., CAR T cell therapy: A new era for cancer treatment (Review). Oncology Reports, 2019.

[3] Li, C., et al., Treatment of multiple myeloma: What is the impact on T-cell function? Therapeutic Advances in Hematology, 2024. 15.

[4] Munshi, N.C., et al., Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021. 384(8): p. 705-716.

[5] Pang, Y. and N. Ghosh, Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma. Frontiers in Oncology, 2024. 14.

[6] Shi, D., et al., Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020. 26(15): p. 3979-3989.

[7] Cutri-French, C., et al., CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? Diagnostics (Basel), 2024. 14(8).

[8] Lahiri, A., et al., Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 2023. 22(1).

[9] Chen, L., et al., CAR‐T cell therapy for lung cancer: Potential and perspective. Thoracic Cancer, 2022. 13(7): p. 889-899.

[10] Zhang, X., et al., GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Frontiers in Immunology, 2023. 14.

[11] Chang, Y., & Tian, J. (2024, March 8). New breakthroughs in CAR-T treatment for myasthenia gravis [Newspaper article]. Health News, p. 002.

[12] Mackensen, A., et al., Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med, 2022. 28(10): p. 2124-2132.

[13] Kong, D., et al., Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center. Front Immunol, 2023. 14: p. 1200748.

[14] Seif, M., H. Einsele, and J. Loffler, CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. Front Immunol, 2019. 10: p. 2711.